[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatitis-relapsing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatitis-relapsing":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100639253",false,"NCT07617155","GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis","Effects of GLP-1 Agonists on Prevention of HTG-Induced Acute Pancreatitis Recurrence: Protocol for a Randomized Clinical Trial","RECAP-GLP1","Inclusion Criteria\n\n* Age ≥ 18 years old\n* Previous diagnosis of index HTG-AP (defined as AP with serum TG \\>1000 mg\u002FdL or a serum TG level of 500-1000 mg\u002FdL accompanied by chylous serum)36-38\n* Having HTG as the exclusive cause of AP\n* Time from discharge of index HTG-AP to recruitment between 4 weeks to 3 months, without AP-related symptoms between discharge and recruitment\n* Expression of the willingness to comply with lifestyle modification during the study period.\n* Clinically stable at the time of inclusion\n* The ability to understand the trial and completing it, as evaluated by the investigators.\n* Patients who may get pregnant should ensure using contraceptives for 20 months after inclusion Exclusion Criteria\n* History of malignancy in past 5 years\n* History of hypothyroidism, nephrotic syndrome, Cushing's syndrome or AIDS\n* History of chronic pancreatitis or pancreatic neoplasm\n* History of severe cardiovascular and pulmonary diseases, such as heart failure, coronary heart disease and chronic obstructive pulmonary disease.\n* Severe renal deficiency (glomerular filtration rate \\\u003C 30 ml\u002Fmin)\n* Severe hepatic deficiency (Child-Pugh Class B or C)\n* Previous pancreatic surgery\n* Recurrent AP due to pancreatic diverticulum\n* Recurrent AP due to known genetic mutations (eg. CFTR)\n* Personal or family history of medullary thyroid carcinoma (MTC)\n* Current or prior diagnosis or suspected diagnosis of multiple endocrine neoplasia type 2 (MEN2)\n* Serious hypersensitivity reaction to semaglutide or any of the excipients in the investigational drug or placebo\n* Pregnancy\n* Breast-feeding","ALL","18 Years",{"count":19,"type":20},396,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Hypertriglyceridemia-induced acute pancreatitis (HTG-AP) is associated with a high risk of recurrence despite standard lipid-lowering therapy and lifestyle modification. The goal of this clinical trial is to evaluate whether GLP-1 receptor agonist therapy can reduce the recurrence of HTG-AP in adults with a history of HTG-AP and hypertriglyceridemia.\n\nThe main questions this study aims to answer are:\n\n* Whether GLP-1 receptor agonist therapy reduces the recurrence rate of HTG-AP.\n* Whether GLP-1 receptor agonist therapy improves triglyceride control, body weight, and metabolic parameters.\n* Whether GLP-1 receptor agonist therapy is safe and well tolerated in this patient population.\n\nResearchers will compare GLP-1 receptor agonist therapy plus standard care with standard care alone to determine whether GLP-1 receptor agonist therapy provides additional benefit in preventing recurrent HTG-AP.\n\nParticipants will:\n\n* Receive either GLP-1 receptor agonist therapy plus standard care or standard care alone.\n* Undergo regular clinical follow-up visits and laboratory assessments.\n* Receive monitoring of triglyceride levels, recurrence events, metabolic outcomes, and adverse events during the study period.",[26,27,28,29],"Hypertriglyceridemia Induced Acute Pancreatitis","Recurrent Acute Pancreatitis","Pancreatitis Relapsing","Hypertriglyceridemia",[31,32,33,34,35],"hypertriglyceridemia-induced acute pancreatitis","recurrent acute pancreatitis","semaglutide","GLP-1 receptor agonist","pancreatitis prevention","NOT_YET_RECRUITING","2026-05-28",{"date":39,"type":40},"2026-06-01","ACTUAL",{"date":42,"type":20},"2026-09",{"date":44,"type":20},"2028-12",{"name":46,"class":47},"Peking Union Medical College Hospital","OTHER",""]